Strongyloidiasis

Strongyloidiasis is a helminthic infection caused by the parasitic nematode Strongyloides stercoralis. This microscopic worm, which lives primarily in the human intestine, can cause a range of clinical manifestations that can range from asymptomatic carriage to severe forms of the disease accompanied by sepsis and organ damage. Infection occurs as a result of contact with contaminated soil containing invasive larvae. The presence of strongyloidiasis is especially dangerous for individuals with a weakened immune response, such as patients with HIV/AIDS, those undergoing organ implantation, or those receiving immunosuppression. Effective diagnosis and treatment of strongyloidiasis are critical to prevent serious complications, as the disease can progress and become life-threatening.

History of the disease and interesting historical facts

Strongyloidiasis has been known since the late 19th century, when it was discovered that the helminthiasis could cause a variety of symptoms in infected people. In 1876, the Austrian parasitologist Friedrich Loeffler was the first to describe the life cycle of Strongyloides stercoralis. In the early 20th century, strongyloidiasis became the subject of active medical research, and as various regions were colonized, statistics on the incidence began to be collected. Despite its recognition in some countries, especially in tropical and subtropical regions, strongyloidiasis remained underrecognized and even ignored in some countries with developed health systems for a long time. In the 1970s, the first large-scale epidemiological assessment was conducted, which demonstrated a high incidence in certain population groups, and subsequent work confirmed the need for more in-depth study of this problem.

Epidemiology

Strongyloidiasis is widespread in tropical and subtropical countries, but can also occur in temperate latitudes, especially among migrants from endemic regions. According to the World Health Organization, the number of people infected with Strongyloides stercoralis is about 30-100 million worldwide. Differences in incidence can be observed depending on geographic location, sanitary conditions, and level of access to health care. In some areas of South and Central America, including Brazil and Paraguay, the incidence can be as high as 25%. There are also suggestions that strongyloidiasis is underestimated in developed countries, as most cases remain undiagnosed, especially among immunocompromised individuals.

Genetic predisposition to this disease

There is currently limited information on genetic susceptibility to strongyloidiasis. However, it is known that certain mutations in genes involved in the immune response may increase the risk of infection. For example, abnormalities in the function of HLA genes may affect the body's ability to recognize and eliminate pathogens. Studies have shown that certain T-cell phenotypes associated with severe disease may indicate an individual's predisposition to a more severe clinical picture of strongyloidiasis. In addition, there is evidence of a link between genetic susceptibility and comorbidities such as diabetes and chronic infectious diseases, which requires further study.

Risk factors for the development of this disease

Risk factors for strongyloidiasis vary and may include:

• Immunocompromised state (includes HIV/AIDS, uncontrolled diabetes and immunosuppressive therapy);
• Geographical location (living in endemic areas such as tropical America, Africa, Asia);
• Work in agriculture or in conditions involving contact with soil;
• Poor sanitation and lack of access to clean water;
• Certain habits, such as digging in the ground with bare feet.

Understanding risk factors is critical for preventing strongyloidiasis in susceptible populations.

Diagnosis of this disease

Diagnosis of strongyloidiasis involves a comprehensive approach that distinguishes this disease from many other infectious processes. Key aspects of diagnosis:

• Main symptoms: dyspeptic disorders, skin rashes, symptoms of bronchial asthma and even irritable bowel syndrome often occur.
• Laboratory tests: The main diagnostic method is microscopic examination of a stool sample to detect S. stercoralis larvae. Serological tests that determine the level of antibodies to the parasite are also possible.
• Radiological examinations: in case of severe course or suspicion of organ damage, X-ray or CT scan may be used to visualize possible pathologies.
• Other types of diagnostics: tissue biopsy is possible in questionable cases.
• Differential diagnosis: Other helminthiasis such as hookworm, as well as bacterial and viral infections are considered to exclude differential diagnoses that may cause a similar clinical picture.

Treatment

Treatment of strongyloidiasis is based on the use of anthelmintic drugs. The main approaches to treatment are:

• General treatment: It is important to take into account the patient's condition, especially the presence of concomitant diseases. It begins with general strengthening of the immune system.
• Pharmacological treatment: the main drugs are ivermectin, albendazole, which have shown high efficiency against Strongyloides stercoralis.
• Surgical treatment: used in rare cases in the presence of complications such as toxic megacolon or intestinal perforation.
• Other treatments: Patients may receive supportive care, including correction of anemia and management of other symptoms.

List of medications used to treat this disease

• Ivermectin;
• Albendazole;
• Mebendazole;
• Praziquantel (in some cases);
• Corticosteroids for allergic reactions and severe disease.

Disease monitoring

Monitoring patients with strongyloidiasis is important to assess the effectiveness of treatment and prevent relapses. The main stages of monitoring are:

• Control steps: regular stool tests and serological tests to ensure the absence of pathogenic larvae.
• Prognosis: With timely diagnosis and treatment, the prognosis is usually favorable. However, in people with weakened immunity, the risk of severe forms remains high.
• Complications: Serious complications may occur, including bowel perforation, sepsis, and in some cases, death.

Age-related features of the disease

Strongyloidiasis may present differently depending on the patient's age. In children, the disease may be less noticeable, but the high risk of severe non-specific manifestations requires careful monitoring. In adults, severe symptoms are often observed, especially in the elderly with underlying medical conditions. The elderly also have an increased risk of complications due to a weakened immune response. Children and the elderly with chronic diseases are more likely to develop severe forms of strongyloidiasis.

Questions and Answers

• What causes strongyloidiasis? Strongyloidiasis is caused by infection with the nematode Strongyloides stercoralis, which enters the body through the skin or mucous membranes.
• What is the main method of diagnosing strongyloidiasis? The main diagnostic method is microscopic analysis of feces for the presence of parasite larvae.
• What symptoms may indicate the presence of strongyloidiasis? The most common symptoms include abdominal pain, diarrhea, skin lesions and possible respiratory reactions.
• How is strongyloidiasis treated? Treatment of strongyloidiasis involves the administration of anthelmintic drugs such as ivermectin and albendazole.
• What is the prognosis for a primary diagnosis of strongyloidiasis? With timely and adequate treatment, the prognosis is usually favorable, but it is important to consider the risk of relapse in people with weakened immune systems.